MedTrace Logo

TTHX1114(NM141) in Combination With DWEK/DSO

NCT04676737 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-11-07

No results posted yet for this study

Summary

Open label, single-treatment, with a concurrent non-treatment control

Conditions

  • Fuchs' Endothelial Dystrophy
  • Fuchs Dystrophy
  • Fuchs

Interventions

DRUG

TTHX1114(NM141)

TTHX1114

Sponsors & Collaborators

  • Trefoil Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Tremblay · Trefoil Therapeutics.com

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-11-16
Completion
2023-01-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676737 on ClinicalTrials.gov